IntroductionMulti-ingredient nutritional supplements combining insulin-sensitizing and anti-androgenic compounds are increasingly used in polycystic ovary syndrome (PCOS), yet evidence on their combined clinical effects remains limited.This study aimed to evaluate whether the use of a multi-ingredient nutritional supplement blend containing myo-inositol, α-lipoic acid, N-acetylcysteine, saw palmetto, and folic acid was associated with six-month changes in body mass index (BMI), menstrual-cycle characteristics, and Ferriman-Gallwey hirsutism scores in women with PCOS. MethodsThirty-five Lebanese women with PCOS aged 18 to 40 and not receiving metformin or hormonal therapy were enrolled.BMI, menstrual cycle frequency, and Ferriman-Gallwey hirsutism scores were assessed at baseline.Hirsutism was reassessed at two and six months, while BMI and cycle regularity were reassessed at six months.Paired analyses and a linear mixed-effects model for repeated Ferriman-Gallwey scores were applied as appropriate, with significance set at p < 0.05.Three participants were lost to follow-up. ResultsAt six months (N=32), mean BMI decreased significantly from 26.5 ± 2.8 to 25.7 ± 2.5 kg/m² among participants with complete paired BMI data (mean change = -0.88 ± 1.56 kg/m²; p = 0.003).Ferriman-Gallwey scores declined from 15.3 ± 3.2 at baseline to 15.1 ± 3.0 at 2 months and 14.4 ± 2.6 at 6 months.In a linear mixed-effects model, the baseline-to-six-month reduction remained statistically significant (mean difference: -1.08; 95% CI: -1.38 to -0.77; Holm-adjusted p < 0.001), while the smaller baseline-to-two-month change did not remain statistically significant after adjustment for multiple comparisons.Menstrual cycle regularity showed a non-significant improving trend (regular cycles: 8.6% to 18.8%; p=0.250). ConclusionsSix months of using the supplement blend was associated with a modest reduction in BMI and a statistically significant but small baseline-to-six-month reduction in Ferriman-Gallwey hirsutism scores, with no statistically significant improvement in menstrual-cycle regularity.These observational findings should be interpreted as preliminary and support further randomized controlled trials with standardized lifestyle monitoring, objective metabolic and hormonal outcomes, and systematic safety assessment.
No takes yet. Share an insight, caveat, or question.
Abdelrazzak et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: